“The Queensland Facility for Advanced Bioinformatics Selects IPA in ... - PR Newswire” plus 4 more |
- The Queensland Facility for Advanced Bioinformatics Selects IPA in ... - PR Newswire
- Three Americans share Nobel Prize for work in cell biology - New London Day
- Science Day on Madison campus to honor biology mentor's legacy - Recorder Community Newspapers
- Davis High grad wins Nobel Prize - Woodland Daily Democrat
- DNA Transistor’ Could Revolutionize Genetic Testing - Wired News
The Queensland Facility for Advanced Bioinformatics Selects IPA in ... - PR Newswire Posted: 06 Oct 2009 06:57 AM PDT REDWOOD CITY, Calif., Oct. 6 /PRNewswire/ -- Ingenuity Systems, the leading provider of information solutions for life science researchers, and Millennium Science, Ingenuity Systems' exclusive distributor for Australia and New Zealand, today announced a multi-year deal for Ingenuity Pathway Analysis (IPA) with the Queensland Facility for Advanced Bioinformatics (QFAB). IPA will become a significant component of a unique Integrated Systems Biology platform that has been funded by the Australian Research Council in partnership with the Australian Stem Cell Centre and other institutions. IPA will be used for data analysis and interpretation as part of QFAB's initiative to enable the global efforts of biotechnology, research biology, drug discovery, and translational medicine. As part of the bioinformatics platform, IPA will serve as the primary solution to model, analyze, and identify key insights from high-throughput biomolecular data and curated datasets relating to health, biotechnology, and environmental processes. IPA will also help explore biomolecular network models and facilitate experimental validation. "QFAB felt that IPA's powerful capabilities made it the perfect solution to include in a unique, state-of-the-art systems biology platform, and we are excited that this integration will help bring better biological insights to our customers in the Australia and the Asia-Pacific regions," stated Jeremy Barker, Chief Executive Officer, Queensland Facility for Advanced Bioinformatics. "Advances in technology make it possible to capture and integrate more sophisticated types of data, yet the challenge is still interpreting the results and making informed conclusions. IPA is the ideal tool to rapidly make sense of complex data, which is why we are excited that the QFAB will use IPA as part of its platform," added Sean Scott, Senior Vice President, Commercial Operations, Ingenuity Systems. Bren Collinson, Managing Director of Millennium Science, concluded, "This deal highlights the importance of developing and maintaining a solid relationship between Millenium, our customers, and our suppliers, and we are looking forward to working together with QFAB and Ingenuity in the future." About Ingenuity Pathways Analysis Ingenuity Pathways Analysis is an all-in-one software application that enables researchers to model, analyze, and understand the complex biological and chemical systems at the core of life science research. IPA's search capabilities provide users with access to the highest quality detail-rich knowledge available on genes, drugs, chemicals, protein families, cellular and disease processes, and signaling and metabolic pathways. IPA supports analysis of data from all experimental platforms, and is used at all stages of the drug discovery and development process, including target identification and validation, biomarker discovery, molecular toxicology, metabolomics, and pharmacogenomics. IPA has been broadly adopted and cited in hundreds of peer-reviewed journals. About Ingenuity Systems(R) Ingenuity Systems is a leading provider of information solutions and custom services for life science researchers, computational biologists and bioinformaticists, and life science industry suppliers. Our long-term focus on innovation in semantic search has allowed us to create groundbreaking technologies that have one common goal --to generate maximum value from all types of biological and chemical knowledge. Ingenuity offerings leverage the Ingenuity Knowledge Base, which contains uniquely structured literature findings that allow scientists to ask complex biological questions and gain rapid insight into their experimental data or systems of interest. Today, Ingenuity's solutions are used by thousands of researchers at hundreds of leading pharmaceutical, biotechnology, academic, and government research institutions worldwide. For more information visit: www.ingenuity.com About Millennium Science Millennium Science is a distributor of life science products throughout Australia & New Zealand. Our portfolio is representative of some of the best manufacturers in the business across the disciplines of genomics, proteomics, cell biology and automation. Our ethos is simple: enable your next-generation research. SOURCE Ingenuity Systems Website: http://www.ingenuity.com |
Three Americans share Nobel Prize for work in cell biology - New London Day Posted: 06 Oct 2009 02:47 AM PDT The Nobel Prize in Physiology or Medicine was awarded Monday to three American scientists who solved a problem of cell biology with deep relevance to cancer and aging. The three will receive equal shares of a prize worth around $1.4 million. The recipients solved a longstanding puzzle involving the ends of chromosomes, the giant molecules of DNA that embody the genetic information. These ends, called telomeres, get shorter each time a cell divides and so serve as a kind of clock that counts off the cell's allotted span of life. The three winners are Elizabeth H. Blackburn of the University of California, San Francisco, Carol W. Greider of Johns Hopkins University School of Medicine and Jack W. Szostak of Massachusetts General Hospital. The discoveries were made some 20 years ago in pursuit of a purely scientific problem that seemingly had no practical relevance. But telomeres have turned out to play a role in two medical areas of vast importance, those of aging and cancer, because of their role in limiting the number of times a cell can divide. Greider saw the prize as an award for curiosity with no practical goal in mind. "I am thrilled that the basic science can be celebrated," she said in an interview Monday. Though Americans have once again made a clean sweep of the Nobel medicine prize, two of the three winners are immigrants. Blackburn was born in Tasmania, Australia, and has dual citizenship; Szostak was born in London. The field of telomere research grew out of a puzzle in the mechanics of copying DNA. The copying enzyme works in such a way that one of the two strands of the double helix is left a little shorter after each division. Work by the three winners and others led to the discovery of telomerase, a special enzyme that can prevent the shortening by adding extra pieces of DNA. This piece of basic biology soon turned out to have important implications for aging and cancer. Telomerase is usually active only at the beginning of life; thereafter the telomeres get shorter each time a cell divides. If they get too short, a cell is thrown into senescence and cannot divide. Short telomeres are known to have a role in certain diseases of aging, like aplastic anemia. Telomeres are also important in cancer, a disease in which control of cell proliferation is lost. Cancer cells need to reactivate the telomerase gene, or their telomeres will get steadily shorter, forcing them into senescence. In some 80 to 90 percent of human cancer cells, the telomerase gene has been switched back on, Blackburn said. Geron Corp. has two clinical trials under way, one of a drug and one of a vaccine, to see whether cancers can be treated by inhibiting telomerase. |
Science Day on Madison campus to honor biology mentor's legacy - Recorder Community Newspapers Posted: 05 Oct 2009 09:53 PM PDT She held a bachelor's degree from James Millikin University, Decatur, Ill.; a master's degree from the University of Illinois, and a doctoral degree from New York University. Past And Future "Just as Dr. Phillips is an important part of the history of science at Drew, she is also of equal importance to its future," said Ross. "Through her estate, the university will receive an extremely generous gift, which will improve science education for Drew students in the decades ahead." Future science students who would benefit from Phillips' bequest will be on the Drew campus on Oct. 12 for the school's Science Day Open House, a program designed for college-bound high school students interested in a scientific course of study at Drew. Holding the open house and the celebration of Phillips' career on the same day, according to Ross, is a fitting tribute.
• The first of three events in Phillips' honor, a showcase of Drew students' summer research, will begin at 2:15 p.m. in Mead Hall. All student presenters were participants in last season's Drew Summer Science Institute, a "hands-on" research program for undergraduates. Their projects focused on such topics as learning and memory, air pollution and antibiotic drugs.
• At 4:30 p.m. in Room 4 in the Hall of Sciences, the program will continue with a talk by biology professors Roger Knowles, Stephen Dunaway and David Miyamoto. The three will speak on their respective research endeavors, including Alzheimer's disease, cell division in cancer patients, and embryonic development.
• The celebration of Phillips' life and career will conclude with a 6 p.m. buffet dinner in Mead Hall.
|
Davis High grad wins Nobel Prize - Woodland Daily Democrat Posted: 06 Oct 2009 08:59 AM PDT Carol W. Greider, a professor in the department of molecular biology and genetics at Baltimore's Johns Hopkins University School of Medicine, center, stands with her daughter Gwendolyn Comfort, 9, left, and son Charles Comfort, 13, right, after a news conference in Baltimore, Monday. Greider, along with two other Americans, won the 2009 Nobel Prize in medicine on Monday for discovering a key mechanism in the genetic operations of cells, an insight that has inspired new lines of research into cancer. (Rob Carr/Associated Press) She shares the honor with fellow Americans Elizabeth H. Blackburn and Jack W. Szostak. The research by Greider Blackburn, and Szostak revealed the workings of chromosome features called telomeres, which play an important role in the aging of cells. It's the first time two women have shared in a single Nobel science prize. Over the years, a total of 10 women have won the prize in medicine. Blackburn, 60, who holds U.S. and Australian citizenship, is a professor of biology and physiology at the University of California, San Francisco. Greider, 48, is a professor in the department of molecular biology and genetics at Johns Hopkins University School of Medicine in Baltimore. London-born Szostak, 56, is a professor of genetics at Harvard Medical School and a researcher with the Howard Hughes Medical Institute. Their work, done in the 1970s and 1980s, showed how features at the tips of chromosomes -- telomeres -- can keep them from getting progressively shorter as cells divide. It's been compared to the way plastic tips on the ends of shoelaces keep the laces from fraying. Blackburn and Greider discovered an enzyme, telomerase (teh-LAH-meh-race), that maintains the lengths of the telomeres. Later research has shown that telomerase is switched on in almost all cancers.Telomerase is active before birth, when cells are dividing rapidly. By age 4 or 5 it's basically shut off in almost all cells. That means the telomeres degrade over time, leading those cells to age and eventually stop dividing. But scientists have shown that adding telomerase to human cells can extend their lifespan indefinitely. Such research spurred speculation that telomerase might turn out to be a fountain of youth. But experts say that aging is more complicated than just changes in telomeres. Scientists are still studying what impact telomeres might have; perhaps they will reveal ways to ward off some aspects of aging, researchers say. Still other work showed that telomerase helps cancer cells sustain their uncontrolled growth. Scientists are trying to exploit that to produce new therapies, noted Jerry Shay of the University of Texas Southwestern Medical Center in Dallas. The farthest along is a vaccine-like approach, which trains the immune system to home in on telomerase as a way to identify and attack cancerous cells. Other approaches attempt to use it as a signal that activates a cell-killing virus, or to devise a drug to block the enzyme's effect, he said. Shay said he believes some kind of telomerase-based cancer treatment will become available within four years. Monday's prize "is totally well-deserved," Shay said. "These people were clearly the forerunners of what is now becoming a much stronger field that has lots of interesting questions, (and that is) likely to have a major importance in medicine in the future." The prize includes $1.4 million, split among the three winners. Szostak, meeting with reporters, joked that he might use the money to send his two elementary school-age children to college. "They might like that," he quipped. As for his work on telomeres, Szostak decided "it was time to move on" to another field. His current research is focused on the origins of life. At a news conference in San Francisco, Blackburn joked that she had gone through the five stages of happiness after the phone rang in the middle of the night. "I went through, 'Where's the phone?' to disbelief to dazed to, 'I think it's sinking in now," to, 'I'm just so happy."' Greider, in Baltimore, said she was telephoned just before 5 a.m. with the news that she had won. "It's really very thrilling, it's something you can't expect," she told The Associated Press by telephone. Later, she said the award was "really a tribute to curiosity-driven basic science." Nobel judges say women are underrepresented in Nobel statistics because the award-winning research often dates back several decades to a time when science was dominated by men. Still, critics say the judges aren't looking hard enough for deserving women candidates. The Nobel Prizes in physics, chemistry, literature and the Nobel Peace Prize will be announced later this week, while the economics award will be presented on Oct. 12. |
DNA Transistor’ Could Revolutionize Genetic Testing - Wired News Posted: 06 Oct 2009 08:23 AM PDT Researchers at IBM have found a way to meld biology and computing to create a new chip that could become the basis for a fast, inexpensive, personal genetic analyzer. The DNA sequencer involves drilling tiny nanometer-size holes through computer-like silicon chips, then passing DNA strands through them to read the information contained in their genetic code. "We are merging computational biology and nanotechnology skills to produce something that will be very useful to the future of medicine," Gustavo Stolovitzky, an IBM researcher, told Wired.com. The "DNA transistor" could make it faster and cheaper to sequence individuals' complete genomes. In so doing, it could help facilitate advances in bio-medical research and personalized medicine. For instance, having access to a person's genetic code could help doctors create customized medicine and determine an individual's predisposition to certain diseases or medical conditions. Such a device could also reduce the cost of personalized genome analysis to under $1,000. In comparison, the first complete sequencing of a human genome, done by the Human Genome Project, cost about $3 billion when it was finally completed in 2003. Since then, other efforts have attempted to achieve something similar for a much lower cost. Stanford researcher Stephen Quake recently showed the Heliscope Single Molecule Sequencer that can sequence a human genome in about four weeks at a cost of $1 million. Services such as 23&me offer DNA testing for much less, but only do partial scans, identifying markers for specific diseases and genetic traits rather than mapping the entire genome. Because of the expense, so far only seven individuals' genomes have been fully sequenced. IBM's personalized DNA readers, if successful, could extend that privilege to many more people. "If there's a chance that this could go behind the counter at hospitals, clinics and someday even a black bag then it would change how we approach medicine," says Richard Doherty, research director at consulting firm Envisioneering Group. "All it would take is a simple test to look at anyone genes." DNA, or Deoxyribonucleic acid, contains the instructions needed for an organism to develop, survive and reproduce. A gene comprises the set of instructions needed to make a single protein. For humans, the complete genome contains about 20,000 genes on 23 pairs of chromosomes. IBM scientists hope to change that by taking advantage of current chip-fabrication technology. Researchers took a 200-millimeter silicon-wafer chip and drilled a 3-nanometer-wide hole (known as a nanopore) through it. A nanometer is one one-billionth of a meter or about 100,000 times smaller than the width of a human hair. The DNA is passed through the nanopore. To control the speed at which it flows through the pore, researchers developed a device that has a multilayer metal and dielectric structure, says Steve RossNagel, a researcher at IBM's Watson lab in New York. This metal-dielectric structure holds the nanopore. A modulated electric field between the metal layers traps the DNA in the nanopore. Since the molecule is easily ionized, voltage drops across the nanopore help "pull" the DNA through. By cyclically turning on and off these gate voltages, scientists can move the DNA through the pore at a rate of one nucleotide per voltage cycle –- a rate the researchers believe would make the DNA readable. IBM hasn't specified how fast a strand of DNA can be read, though researchers say a fully functional device could sequence the entire genome in "hours." Ultimately, several such nanopores can run parallel on a chip to create a complete genomic analyzer. Though researchers have figured out the basics, it could still take up to three years to get a working prototype. The challenge now is to slow and control the motion of the DNA through the hole so the reader can accurately decode what is in the DNA. They also need to determine exactly how the DNA will be decoded when it passes through the nanopore. It's an area of "intense research" within and outside of IBM, says Stolovitzky. One way to do it would be to measure the electrical properties of the different DNA bases such as capacitance and conductivity. "This is a knowledge that most people would like to have," says RossNagel. "If we could have a big enough database of human genomes then you can see the interplay of genetics. That would change how we approach medicine." Top Photo: A cross section of IBM's DNA Transistor simulated on the Blue Gene supercomputer shows a single stranded DNA moving in the midst of invisible water molecules through the nanopore/ IBM See Also:
In the video below, IBM researchers explain how they came up with the idea for the DNA Transistor. The video includes an animated simulation showing a DNA strand moving through the nanopore. |
You are subscribed to email updates from Biology - Bing News To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
Google Inc., 20 West Kinzie, Chicago IL USA 60610 |
0 comments:
Post a Comment